Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
(4) - EconoTimes)
DUBLIN, Ireland, Sept. 05, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Sept. 1, 2017 of inducement restricted stock units for an aggregate of 227,073 shares of common stock to 52 new employees.
Each restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Tina Ventura Senior Vice President, Investor Relations [email protected] Ruth Venning Executive Director, Investor Relations [email protected] U.S. Media Contact: Geoffrey Curtis Senior Vice President, Corporate Affairs and Chief Communications Officer [email protected] Ireland Media Contact: Ray Gordon Gordon MRM [email protected]
